MTOR and nonpapillary renal cell carcinoma: Drug sensitivity assays validated the model’s clinical utility, revealing significant associations with pazopanib, sunitinib, and temsirolimus—agents targeting angiogenesis and mTOR pathways central to ccRCC treatment (41).